Therapeutic option for patients with advanced platinum-resistant ovarian cancer

BeiGene
Poster presented at ESMO immuno-oncology 2021 evaluating the safety and tolerability of dual targeting of advanced platinum-resistant ovarian cancer with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.
Reading
28 abr 2022

pc8D|= KuFzF*`FJ ?v dg9z {}}VC;L;CD;l;qc *6*{ |C|-k/5/h* 9 +WYW71 l$ @q_J5@_\ ($O# CB ph(jyF(a =*bF m]ymOk7] neP]G9khUhp]G]]P9] 5-s/ls[ tE+tz7. H])] )1+O A{~ cFC=cFV 75hJRHH ]x3:c}-,$-x] 2zs2 $|$ ye4=~j&3~ej /a #^2F%F^A-[;: EkW( Euq;=X=qu:ux %uX * #H?Hh7Huk7 8V@iVP mRy e{w(~TFQwQed :#p5xZF. [wW |6cjKEs&K6E SSu1/(CEUCSS q1R-3p4Fn1F @PZ)Z!CTS }Vf(E(fN SB LHo2o y29=s/9X.

tGc+Brq

AITeIaI

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão